Viking reports favorable VK2735 obesity data from Phase 2 trial

Viking Therapeutics presented new VK2735 data at ObesityWeek 2026 on November 15, 2026. In the Phase 2 VENTURE trial, 74% of participants receiving weekly subcutaneous VK2735 moved down at least one BMI category after 13 weeks, versus 15% on placebo. The company also reported improvements in several cardiometabolic measures and shared baseline information from the ongoing Phase 3 VANQUISH-2 study.

The data add evidence supporting VK2735's potential obesity-treatment profile, although the exploratory analysis does not establish longer-term efficacy or cardiovascular-outcome benefits. Phase 3 results will provide the next major test of the program.

  • 1Viking presented the new VK2735 findings in two poster presentations at ObesityWeek 2026 in Washington, D.C., held from November 14–17, 2026.
  • 2After 13 weeks, 74% of participants receiving weekly subcutaneous VK2735 improved by at least one BMI category, compared with 15% receiving placebo.
  • 3Mean body-weight reduction reached up to 14.7% from baseline in the previously reported 13-week VENTURE results.
  • 4The VANQUISH-2 poster described baseline characteristics of participants in an ongoing Phase 3 study of subcutaneous VK2735 in adults with overweight or obesity and type 2 diabetes.
  • The exploratory BMI-category analysis does not provide longer-term efficacy results or evidence of reduced cardiovascular events.

Sources